FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135073908> ?p ?o ?g. }

• W3135073908 endingPage "828" @default.
• W3135073908 startingPage "820" @default.
• W3135073908 abstract "Bruton’s tyrosine kinase (BTK) is a target for treatment of hematologic malignancies and autoimmune diseases. TAK‐020 is a highly selective covalent BTK inhibitor that inhibits both B cell receptor and fragment crystallizable receptor signaling. We assessed the safety/tolerability and pharmacokinetics/pharmacodynamics (PDs) of TAK‐020 in healthy subjects. Each cohort of the single‐rising dose ( n = 72; 9 cohorts) and the multiple‐rising dose ( n = 48; 6 cohorts) portions of the study comprised six TAK‐020‐treated and two placebo‐treated, subjects aged 18–55 years (inclusive). The PD effects were assessed by measuring BTK occupancy and the inhibition of fragment crystallizable epsilon receptor 1 (FcεRI)‐mediated activation of basophils. Overall, treatment‐emergent adverse events (TEAEs) were similar to placebo; there were no serious TEAEs or no TEAEs leading to discontinuation. TAK‐020 was rapidly absorbed (median time to maximum plasma concentration (T max ) 45–60 minutes) with a half‐life of ~ 3–9 hours at doses ≥ 2.5 mg. TAK‐020 exposure was generally dose proportional for single doses ≤ 70 mg and after multiple doses of ≤ 60 mg once daily. Target occupancy was dose dependent, with doses ≥ 2.5 mg yielding maximum and sustained occupancy > 70% for > 96 hours. Single doses ≥ 4.4 mg reduced FcεRI‐mediated activation of basophils by > 80% and comparable inhibition was observed with daily dosing ≥3.75 mg for 9 days. Inhibition persisted for 24–72 hours postdose and the duration generally increased with dose. TAK‐020 was generally well‐tolerated in healthy subjects after single and multiple doses and demonstrated target engagement and pathway modulation. The PD effects outlasted drug exposures, as expected for covalent inhibition of BTK." @default.
• W3135073908 created "2021-03-15" @default.
• W3135073908 creator A5040025213 @default.
• W3135073908 creator A5041293213 @default.
• W3135073908 creator A5044409463 @default.
• W3135073908 creator A5059264263 @default.
• W3135073908 creator A5065132124 @default.
• W3135073908 creator A5072446366 @default.
• W3135073908 creator A5080943557 @default.
• W3135073908 creator A5081579877 @default.
• W3135073908 date "2021-03-02" @default.
• W3135073908 modified "2023-10-17" @default.
• W3135073908 title "A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Single‐Dose and Multiple‐Rising‐Dose Study of the BTK Inhibitor TAK‐020 in Healthy Subjects" @default.
• W3135073908 cites W1647059547 @default.
• W3135073908 cites W1979373806 @default.
• W3135073908 cites W2032874971 @default.
• W3135073908 cites W2091347081 @default.
• W3135073908 cites W2108485092 @default.
• W3135073908 cites W2117403402 @default.
• W3135073908 cites W2171771895 @default.
• W3135073908 cites W2338965822 @default.
• W3135073908 cites W2463303740 @default.
• W3135073908 cites W2775637672 @default.
• W3135073908 cites W2944582362 @default.
• W3135073908 cites W2981743016 @default.
• W3135073908 doi "https://doi.org/10.1111/cts.12871" @default.
• W3135073908 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8212709" @default.
• W3135073908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33650758" @default.
• W3135073908 hasPublicationYear "2021" @default.
• W3135073908 type Work @default.
• W3135073908 sameAs 3135073908 @default.
• W3135073908 citedByCount "4" @default.
• W3135073908 countsByYear W31350739082021 @default.
• W3135073908 countsByYear W31350739082023 @default.
• W3135073908 crossrefType "journal-article" @default.
• W3135073908 hasAuthorship W3135073908A5040025213 @default.
• W3135073908 hasAuthorship W3135073908A5041293213 @default.
• W3135073908 hasAuthorship W3135073908A5044409463 @default.
• W3135073908 hasAuthorship W3135073908A5059264263 @default.
• W3135073908 hasAuthorship W3135073908A5065132124 @default.
• W3135073908 hasAuthorship W3135073908A5072446366 @default.
• W3135073908 hasAuthorship W3135073908A5080943557 @default.
• W3135073908 hasAuthorship W3135073908A5081579877 @default.
• W3135073908 hasBestOaLocation W31350739081 @default.
• W3135073908 hasConcept C111113717 @default.
• W3135073908 hasConcept C112705442 @default.
• W3135073908 hasConcept C126322002 @default.
• W3135073908 hasConcept C142724271 @default.
• W3135073908 hasConcept C170493617 @default.
• W3135073908 hasConcept C197934379 @default.
• W3135073908 hasConcept C204787440 @default.
• W3135073908 hasConcept C27081682 @default.
• W3135073908 hasConcept C2777288759 @default.
• W3135073908 hasConcept C2778375690 @default.
• W3135073908 hasConcept C2778715236 @default.
• W3135073908 hasConcept C42362537 @default.
• W3135073908 hasConcept C71924100 @default.
• W3135073908 hasConcept C79410662 @default.
• W3135073908 hasConcept C90059517 @default.
• W3135073908 hasConcept C90924648 @default.
• W3135073908 hasConcept C98274493 @default.
• W3135073908 hasConceptScore W3135073908C111113717 @default.
• W3135073908 hasConceptScore W3135073908C112705442 @default.
• W3135073908 hasConceptScore W3135073908C126322002 @default.
• W3135073908 hasConceptScore W3135073908C142724271 @default.
• W3135073908 hasConceptScore W3135073908C170493617 @default.
• W3135073908 hasConceptScore W3135073908C197934379 @default.
• W3135073908 hasConceptScore W3135073908C204787440 @default.
• W3135073908 hasConceptScore W3135073908C27081682 @default.
• W3135073908 hasConceptScore W3135073908C2777288759 @default.
• W3135073908 hasConceptScore W3135073908C2778375690 @default.
• W3135073908 hasConceptScore W3135073908C2778715236 @default.
• W3135073908 hasConceptScore W3135073908C42362537 @default.
• W3135073908 hasConceptScore W3135073908C71924100 @default.
• W3135073908 hasConceptScore W3135073908C79410662 @default.
• W3135073908 hasConceptScore W3135073908C90059517 @default.
• W3135073908 hasConceptScore W3135073908C90924648 @default.
• W3135073908 hasConceptScore W3135073908C98274493 @default.
• W3135073908 hasIssue "3" @default.
• W3135073908 hasLocation W31350739081 @default.
• W3135073908 hasLocation W31350739082 @default.
• W3135073908 hasLocation W31350739083 @default.
• W3135073908 hasOpenAccess W3135073908 @default.
• W3135073908 hasPrimaryLocation W31350739081 @default.
• W3135073908 hasRelatedWork W1934667138 @default.
• W3135073908 hasRelatedWork W2037651778 @default.
• W3135073908 hasRelatedWork W2052463334 @default.
• W3135073908 hasRelatedWork W2090169689 @default.
• W3135073908 hasRelatedWork W2108772785 @default.
• W3135073908 hasRelatedWork W2329478898 @default.
• W3135073908 hasRelatedWork W3021369409 @default.
• W3135073908 hasRelatedWork W3087516196 @default.
• W3135073908 hasRelatedWork W4298086959 @default.
• W3135073908 hasRelatedWork W4309706764 @default.
• W3135073908 hasVolume "14" @default.
• W3135073908 isParatext "false" @default.
• W3135073908 isRetracted "false" @default.
• W3135073908 magId "3135073908" @default.

• next